Finanzen von Marker Therapeutics Inc (MRKR)MRKRMarker Therapeutics Inc

Evaluating the bottom line, Marker Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -76.87%, provide a clear picture of how effectively MRKR converts its operational activities into shareholder value.

In the context of the broader market, MRKR competes directly with industry leaders such as BNGO and AQB. With a market capitalization of $15.28M, it holds a leading position in the sector. When comparing efficiency, MRKR's gross margin of N/A stands against BNGO's 52.80% and AQB's N/A. Such benchmarking helps identify whether Marker Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Marker Therapeutics has shown a decline in revenue, with a reported $3.55 million in revenue for the last fiscal year, a 46.1% year-over-year decrease. The company has also been consistently posting negative earnings per share (EPS), with the latest EPS at -0.79, indicating ongoing financial challenges.